Atheroregressive Potential of the Treatment with a Chimeric Monoclonal Antibody against Sulfated Glycosaminoglycans on Pre-existing Lesions in Apolipoprotein E-Deficient Mice

• Egile Nagusiak: Victor Brito (Egilea), Katia Mellal (Egilea), Karina F. Zoccal (Egilea), Yosdel Soto (Egilea), Liliane Ménard (Egilea), Roger Sarduy (Egilea), Lucia H. Faccioli (Egilea), Huy Ong (Egilea), Ana M. Vázquez (Egilea), Sylvie Marleau (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2017-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The retention of lipoprotein particles in the intima, in particular to glycosaminoglycan side chains of proteoglycans, is a critical step in atherosclerosis initiation. Administration of chP3R99, a chimeric mouse/human monoclonal antibody inducing an anti-idiotypic network response against glycosami...